1. Home
  2. CPRX vs HCM Comparison

CPRX vs HCM Comparison

Compare CPRX & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPRX
  • HCM
  • Stock Information
  • Founded
  • CPRX 2002
  • HCM 2000
  • Country
  • CPRX United States
  • HCM Hong Kong
  • Employees
  • CPRX N/A
  • HCM N/A
  • Industry
  • CPRX Biotechnology: Pharmaceutical Preparations
  • HCM Biotechnology: Pharmaceutical Preparations
  • Sector
  • CPRX Health Care
  • HCM Health Care
  • Exchange
  • CPRX Nasdaq
  • HCM Nasdaq
  • Market Cap
  • CPRX 2.6B
  • HCM 2.5B
  • IPO Year
  • CPRX 2006
  • HCM N/A
  • Fundamental
  • Price
  • CPRX $19.83
  • HCM $14.98
  • Analyst Decision
  • CPRX Strong Buy
  • HCM Strong Buy
  • Analyst Count
  • CPRX 6
  • HCM 1
  • Target Price
  • CPRX $32.83
  • HCM $28.00
  • AVG Volume (30 Days)
  • CPRX 1.4M
  • HCM 37.6K
  • Earning Date
  • CPRX 08-06-2025
  • HCM 08-07-2025
  • Dividend Yield
  • CPRX N/A
  • HCM N/A
  • EPS Growth
  • CPRX 183.96
  • HCM N/A
  • EPS
  • CPRX 1.65
  • HCM 0.53
  • Revenue
  • CPRX $558,499,000.00
  • HCM $602,197,000.00
  • Revenue This Year
  • CPRX $16.37
  • HCM $15.00
  • Revenue Next Year
  • CPRX $8.80
  • HCM $19.91
  • P/E Ratio
  • CPRX $11.91
  • HCM $6.03
  • Revenue Growth
  • CPRX 28.55
  • HCM N/A
  • 52 Week Low
  • CPRX $16.06
  • HCM $11.51
  • 52 Week High
  • CPRX $26.58
  • HCM $21.50
  • Technical
  • Relative Strength Index (RSI)
  • CPRX 37.75
  • HCM 36.04
  • Support Level
  • CPRX $19.15
  • HCM $16.91
  • Resistance Level
  • CPRX $22.53
  • HCM $18.17
  • Average True Range (ATR)
  • CPRX 0.73
  • HCM 0.49
  • MACD
  • CPRX -0.03
  • HCM -0.32
  • Stochastic Oscillator
  • CPRX 24.26
  • HCM 4.89

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

About HCM HUTCHMED (China) Limited

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Share on Social Networks: